{"prompt": "['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_59', '12 months of Rebif treatment', 'ARR before study entry compared to ARR at study end', 'Association between ARR and treatment adherence.', 'Data Sources', 'The source of information will be data collected from the medical', 'records, prescription records, laboratory reports and/or routine', 'interview of patients. Data will be entered into the electronic case', 'report form by the Investigator site staff.', 'Study Size', '133 patients diagnosed with RRMS will be enrolled (63 in the', 'Netherlands, 40 in Switzerland and 30 in Belgium).', 'Sample size', 'A sample size of 106 subjects will be required to have 85% power to', 'justification', 'detect at least an 8 point difference in mean TSQM scores between', 'Baseline and Month 6 or Month 12 measurements, with the standard', 'deviation of 27.5 and a two sided significance level of 5%. Assuming a', '20% dropout rate, approximately 133 patients will be enrolled into the', 'study in the Netherlands, Switzerland and Belgium.', 'Data Analysis', 'Statistical analysis will be mainly descriptive. Descriptive statistics (n,', 'mean, standard deviation, median, first quartile [Q1], third quartile', '[Q3], minimum, maximum) will be provided for continuous variables.', 'Frequencies and percentages will be presented for categorical and', 'ordinal variables. Where appropriate, 95% confidence intervals (CIs)', 'will be presented.', 'All analyses will be performed on subjects who received at least one', 'dose of Rebif following enrollment in the study.', 'Primary Endpoint analysis:', 'A paired two-sided t-test of the global satisfaction score (TQSM score)', 'will be used to test the null hypothesis that there is no difference in the', 'global satisfaction score (TQSM score) between 6, 12 months and', 'Baseline. The corresponding 95% two-sided CI will be presented.', 'Secondary Endpoint analysis:', 'ARR and its associated 95% CI before study entry and after 12 months', 'of Rebif treatment will be summarized overall and by previous MS', 'therapy.', 'Reasons for discontinuation of previous therapy and adherence after 6', 'and 12 months of Rebif treatment will be summarized descriptively', 'and overall.', 'CONFIDENTIAL', '15/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_591', 'Changes in MusiQoL after 6 and 12 months of Rebif treatment versus', 'Baseline will be analysed using same methodology as for Primary', 'Endpoint.', 'Analysis of additional Secondary Endpoints as correlation analysis', 'between TSQM and MusiQoL versus ARR, adherence and reason for', 'discontinuation will be described in the statistical analysis plan.', 'Milestones', 'First Patient First Visit (FPFV): September 2016', 'First Patient Last Visit (FPLV): September 2017', 'Last Patient First Visit (LPFV): September 2017', 'Last Patient Last Visit (LPLV): September 2018', 'Database lock: November 2018', 'Final Clinical Study Report: March 2019', 'CONFIDENTIAL', '16/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '5', 'Amendments', 'None', '6', 'Milestones', 'Milestone', 'Planned date', 'Start of data collection', 'September 2016', 'End of data collection', 'September 2018', 'Database lock', 'November 2018', 'Final report of study results', 'March 2019', 'CONFIDENTIAL', '17/60', 'INFORMATION', 'M']\n\n###\n\n", "completion": "END"}